Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about TSHA, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| TSHA-101 | Infantile GM2 Gangliosidosis (Disorder) | Phase 1/2 · NCT04798235 | Active not recruiting |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
TSHA holds $422.8M in cash and short-term investments (as of Sep 30, 2026) and burns about $36.7M/quarter from operations, an estimated runway of 34.6 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 22 · Moderate
We believe that our existing cash and cash equivalents will enable us to fund our operating expenses and capital requirements into the second half of 2028.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when TSHA files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| RA Capital Management, L.P. | Institution (13G, 5%+) | 32,886,242 | 10.09% | 2026-06-30 |
| RTW Investments, LP | Institution (13G, 5%+) | 20,689,084 | 6.35% | 2026-03-31 |
| Vestal Point Capital, LP | Institution (13G, 5%+) | 18,000,000 | 5.52% | 2026-03-31 |
| BlackRock, Inc. | Institution (13G, 5%+) | 17,852,291 | 5.48% | 2025-12-31 |
| Morgan Stanley | Institution (13G, 5%+) | 16,244,339 | 4.98% | 2026-06-30 |
| Sean P. Nolan Chief Executive Officer, Director · +3.19M options |
Insider | 4,443,802 | 1.36% | 2026-01-23 |
| Paul B Manning 10% owner |
Insider | 4,000,000 | 1.23% | 2025-05-30 |
| John A III Stalfort Director · +254,357 options |
Insider | 2,060,849 | 0.63% | 2026-06-01 |
| Kamran Alam CHIEF FINANCIAL OFFICER · +1.45M options |
Insider | 1,442,131 | 0.44% | 2026-02-04 |
| Sukumar Nagendran President and Head of R&D, Director · +1.17M options |
Insider | 936,410 | 0.29% | 2026-07-10 |
| Phillip B. Donenberg Director · +254,357 options |
Insider | 241,289 | 0.07% | 2026-06-01 |
| Alison S Long Director · +254,357 options |
Insider | 127,178 | 0.04% | 2026-06-01 |
Share count 326,045,530 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for TSHA and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →